Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Overview of attention for article published in Cancer Communications, October 2019

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 906 followers.

New article: Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study. https://t.co/C2keYerB0L #kidneycancer #oncology https://t.co/rVOLEY8C1W

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.